Glenmark Pharmaceuticals Peer Comparison

Glenmark Pharmaceuticals Ltd. demonstrates significant challenges in growth and profitability metrics compared to its peers, exhibiting a decline in revenue and negative profit margins, which places it at a disadvantage in the competitive pharmaceuticals sector. This analysis highlights both the underperformance of Glenmark and identifies peer companies that exhibit stronger financial health and growth potential.

• • Glenmark has a negative revenue growth YoY of -9.06% and a negative profit margin of -15.50%.
• • Highest EPS growth is observed in Dr. Reddy's Laboratories (68.07), while Glenmark's EPS is 37.10.
• • Cipla Ltd. leads in ROE with 16.63%, while Glenmark's ROE is significantly lower at 12.56%.
• • Glenmark's PE ratio of 33.79 suggests it is overvalued relative to peers with lower growth prospects.
• • With a debt-equity ratio of 0.2482, Glenmark is in a relatively stable position, but its profitability metrics are concerning.

• • Cipla Ltd.: Strong revenue growth (YoY: 13.28%) and the highest ROE (16.63%) among peers.
• • Dr. Reddy's Laboratories Ltd.: Excellent profitability with a PE of 15.50 and significant revenue growth.
• • Mankind Pharma Ltd.: Outstanding growth trajectory with a YoY revenue increase of 18.12% and strong financial metrics.